Search alternatives:
mg decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
ns decrease » nn decrease (Expand Search), _ decrease (Expand Search), use decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
mg decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
ns decrease » nn decrease (Expand Search), _ decrease (Expand Search), use decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
281
-
282
-
283
-
284
-
285
Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d’Ivoire: A model-based analysis
Published 2019“…In cost-effectiveness analysis, <i>Immediate ART</i> had a 10-year ICER of $680/YLS compared to <i>ART<350/μL</i>, ranging from cost-saving to an ICER of $1,440/YLS as transmission rates varied. …”
-
286
Metformin lotion inhibits scar tissue formation in rat skin after 10 days of wound healing.
Published 2024Subjects: -
287
Metformin lotion elevates p-AMPK in the wounded skin of rats after 10 days of wound healing.
Published 2024Subjects: -
288
Metformin lotion inhibits scar tissue formation in rat skin after 10 days of wound healing.
Published 2024Subjects: -
289
Image_1_IL-12p40/IL-23p40 Blockade With Ustekinumab Decreases the Synovial Inflammatory Infiltrate Through Modulation of Multiple Signaling Pathways Including MAPK-ERK and Wnt.TIF
Published 2021“…No serious adverse events occurred. We observed numerical decreases of all infiltrating cell subtypes at week 12, reaching statistical significance for CD68+ sublining macrophages. …”
-
290
Design and Synthesis of Novel Spiro Derivatives as Potent and Reversible Monoacylglycerol Lipase (MAGL) Inhibitors: Bioisosteric Transformation from 3‑Oxo-3,4-dihydro‑2<i>H</i>‑ben...
Published 2021“…Optimization of the left hand side afforded <b>4f</b> as a promising reversible MAGL inhibitor, which showed potent in vitro MAGL inhibitory activity (IC<sub>50</sub> 6.2 nM), good oral absorption, blood–brain barrier penetration, and significant pharmacodynamic changes (2-arachidonoylglycerol increase and arachidonic acid decrease) at 0.3–10 mg/kg, po. in mice.…”
-
291
-
292
S10 Data -
Published 2024“…The study was conducted with 25%, 50%, and 75% of the upper body weight. Additionally, we varied the starting point (forward tilt and backward tilt) and the direction of rotation. …”
-
293
Supplementary Material for: SGLT2 inhibitors decrease overhydration and proteasuria in patients with chronic kidney disease: a longitudinal observational study
Published 2024“…Results: 42 patients (29 % with diabetic/hypertensive CKD, 31 % with IgA nephropathy; 88 % dapagliflozin 10 mg, 10 % dapagliflozin 5 mg, 2 % empagliflozin 20 mg; median eGFR 46 mL/min/1.73m² and albuminuria 1911 mg/g creatinine) participated in the study. …”
-
294
Supplementary Material for: SGLT2 inhibitors decrease overhydration and proteasuria in patients with chronic kidney disease: a longitudinal observational study
Published 2024“…Results: 42 patients (29 % with diabetic/hypertensive CKD, 31 % with IgA nephropathy; 88 % dapagliflozin 10 mg, 10 % dapagliflozin 5 mg, 2 % empagliflozin 20 mg; median eGFR 46 mL/min/1.73m² and albuminuria 1911 mg/g creatinine) participated in the study. …”
-
295
-
296
-
297
Discovery of New Inhibitors of Hepatitis C Virus NS3/4A Protease and Its D168A Mutant
Published 2019“…Several drugs targeting the protease have been developed, but drug-resistant mutant strains emerged. Here, we screened a library and synthesized a novel class of small molecules based on a tryptophan derivative scaffold identified as HCV NS3/4A protease inhibitors that are active against both wild type and mutant form of the protease. …”
-
298
-
299
-
300